Cumberland Pharmaceuticals Inc
CPIXNasdaqCIK 1087294HealthcareFiscal year ends Dec 31
Reports and events: 324 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2317:01 ET | 8-K | 8.01 Other events | 0001087294-26-000070 |
| 2026-09-1116:51 ET | 8-K/A | 5.07 Shareholder vote results | 0001087294-26-000068 |
| 2026-08-2817:08 ET | 8-K | 7.01 Regulation FD disclosure | 0001087294-26-000064 |
| 2026-08-0717:12 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001087294-26-000062 |
| 2026-08-0417:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001087294-26-000058 |
| 2026-07-1317:28 ET | 8-K | 8.01 Other events | 0001087294-26-000055 |
| 2026-07-0116:15 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-079871 |
| 2026-06-2517:00 ET | 8-K | 5.07 Shareholder vote results | 0001087294-26-000053 |
| 2026-05-0817:02 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001087294-26-000049 |
| 2026-05-0517:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001087294-26-000046 |
| 2026-04-2417:08 ET | 8-K | 5.07 Shareholder vote results | 0001087294-26-000043 |
| 2026-04-2309:01 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-047335 |
| 2026-03-0917:01 ET | DEF 14A | Proxy statementPeriod 2025-12-31 | 0001087294-26-000025 |
| 2026-03-0920:54 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001087294-26-000020 |
| 2026-03-0317:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001087294-26-000015 |
| 2026-02-0417:20 ET | 8-K | 8.01 Other events | 0001087294-26-000011 |
| 2025-11-2420:26 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001087294-25-000023 |
| 2025-11-0717:05 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001087294-25-000020 |
| 2025-11-0417:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001087294-25-000017 |
| 2025-10-2109:25 ET | 8-K | 8.01 Other events | 0001087294-25-000012 |
| 2025-08-0817:03 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001628280-25-039326 |
| 2025-08-0517:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-037923 |
| 2025-05-0917:01 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-024342 |
| 2025-05-0617:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-022753 |
| 2025-04-2815:38 ET | 8-K | 5.07 Shareholder vote results | 0001628280-25-020222 |
| 2025-03-1917:07 ET | 8-K | 8.01 Other events | 0001628280-25-013875 |
| 2025-03-1017:00 ET | DEF 14A | Proxy statementPeriod 2024-12-31 | 0001628280-25-011735 |
| 2025-03-0717:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-011366 |
| 2025-03-0417:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-009967 |
| 2025-02-1917:00 ET | 8-K | 8.01 Other events | 0001628280-25-006430 |
| 2025-02-1416:25 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-005744 |
| 2025-02-0416:37 ET | 8-K | 8.01 Other events | 0001628280-25-003753 |
| 2024-12-0917:04 ET | 8-K | 8.01 Other events | 0001628280-24-050499 |
| 2024-11-1206:55 ET | 8-K | 8.01 Other events | 0001628280-24-046827 |
| 2024-11-0817:04 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-046730 |
| 2024-11-0717:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-046399 |
| 2024-11-0617:12 ET | 8-K | 8.01 Other events | 0001628280-24-045807 |
| 2024-11-0417:15 ET | 8-K | 8.01 Other events | 0001628280-24-045054 |
| 2024-08-0917:03 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001628280-24-036529 |
| 2024-08-0617:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-035262 |
| 2024-05-1016:37 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-022658 |
| 2024-05-0717:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-021185 |
| 2024-04-2916:53 ET | 8-K | 5.07 Shareholder vote results | 0001628280-24-019053 |
| 2024-03-2017:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-012261 |
| 2024-03-1317:03 ET | DEF 14A | Proxy statementPeriod 2023-12-31 | 0001628280-24-010960 |
| 2024-03-1321:14 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001628280-24-010725 |
| 2024-03-0517:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-009006 |
| 2023-11-1308:15 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001628280-23-038418 |
| 2023-11-0717:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-23-037446 |
| 2023-10-1309:11 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-23-034316 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 16:41 ET. Listed shows no prices and gives no investment advice.